Home›Trial›NCT06193928
NCT06193928RECRUITING

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

Study Summary

The objective of this 5-year, prospective, observational cohort study is to evaluate the long-term safety and clinical outcomes of patients with Alagille syndrome (ALGS) or Progressive familial intrahepatic cholestasis (PFIC) treated with Livmarli.

Conditions
Alagille SyndromeProgressive Familial Intrahepatic Cholestasis
Interventions / Drugs
LivmarliLivmarli
View on ClinicalTrials.gov ↗
Sponsor
MIRM
Mirum Pharmaceuticals
Liver Disease
D36/100
Study Details
Enrollment70 participants
Primary Completion—
Lead SponsorMirum Pharmaceuticals, Inc.
Data Retrieved2026-04-11 04:21:18.704691+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 70 participants
Sponsor Catalyst Profile

Mirum Pharmaceuticals (MIRM) is the sponsoring company for this trial. BiotechSign currently grades this company D (36/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

MIRM Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.